Last update 08 May 2025

Dimethyltryptamine

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
2-(3-indolyl)ethyldimethylamine, 3-(2-dimethylaminoethyl)indole, 3-[2-(dimethylamino) ethyl] indole
+ [8]
Action
modulators
Mechanism
5-HT receptor modulators(Serotonin (5-HT) receptor modulators), Neurons modulators
Inactive Indication
Originator Organization-
Drug Highest PhasePhase 2
First Approval Date-
RegulationOrphan Drug (United States)
Login to view timeline

Structure/Sequence

Molecular FormulaC12H16N2
InChIKeyDMULVCHRPCFFGV-UHFFFAOYSA-N
CAS Registry61-50-7

External Link

KEGGWikiATCDrug Bank
---

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Depressive Disorder, Treatment-ResistantPhase 2
Brazil
09 Mar 2022
Depressive DisorderPhase 1-05 Oct 2022
Smoking CessationPhase 1
Netherlands
22 Feb 2022
Brain Injuries, TraumaticPhase 1--
StrokePhase 1--
AlcoholismPreclinical
Israel
01 Mar 2022
Depressive Disorder, MajorPreclinical
United Kingdom
-04 Feb 2021
CognitionPreclinical
Switzerland
01 Dec 2020
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1/2
35
placebo
(Placebo)
tamrcgsgtz(lklqhjdkic) = miuitmgjmf hdqjzabtof (bbanzeabfc, zennubswov - hquhoxoccf)
-
06 Apr 2025
(Ayahuasca)
tamrcgsgtz(lklqhjdkic) = wpkskdbqff hdqjzabtof (bbanzeabfc, ddxheojdui - qkgfvhsxsl)
Phase 1
-
-
jkoppmdckj(bchtuxvhrn) = SPL026 was well tolerated, with an acceptable safety profile, with no serious adverse events bnrhbnyrtt (lfjdiebujr )
-
11 Jan 2024
Phase 1
17
(SSRI Cohort)
(tclioylgte) = suuiembwqt yrehtogccf (cslcdaobqw )
Positive
26 Sep 2023
(Non-SSRI Cohort)
(tclioylgte) = oevdudaotj yrehtogccf (cslcdaobqw )
Phase 2
34
SPL026 21.5mg + supportive therapy
(xpjhmulbyr) = ssaoqxtxru ecsgkphibm (nedsvfragu )
Met
Positive
25 Jan 2023
Placebo + supportive therapy
(pmcriaouhz) = zlmauvkyep xrwfzbkwly (tcmxqejkbx )
Phase 2
30
(zqydggdozp) = No volunteer presented serious adverse events to the 11 different doses tested. rdfnzjmdop (iyxqxywghz )
Positive
04 Nov 2022
Not Applicable
-
556
(lnnpfcdxee) = tkkxhuhyyi gpaefrfyyd (nffquwyien )
Positive
09 Apr 2019
(lnnpfcdxee) = msoboyclfd gpaefrfyyd (nffquwyien )
Not Applicable
520
shhdavocbt(gktoydgytt) = uclzjpltah rovokpjpso (trrlihrfol )
-
09 Oct 2018
Not Applicable
135
GLAT exposure during early pregnancy
kpgmbzhtdm(zpzrvlbhdm) = spvwxwcmbr cwubopohnj (enwtndoblw )
Positive
18 Apr 2017
kpgmbzhtdm(zpzrvlbhdm) = kwthgowvrw cwubopohnj (enwtndoblw )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free